Figure 1B demonstrates that the response of different human cancer cell lines, including breast cancer (HTB26), lung cancer (HTB177 and A549), cervical carcinoma (HTB35), rhabdomyosarcoma (RH30), murine myoblastic sarcoma (C2C12), murine immortalized embryonic (ES-D3), and murine fibroblastic (NIH 3T3) cells, to 1% plasma was much higher than to SDF-1 or HGF, which are known chemoattractants for these cells and employed at supraphysiological concentrations. This evidence concerns the gene CXCL12 and breast cancer.